Literature DB >> 22908169

Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Cornelia B Landersdorfer1, Jurgen B Bulitta, Carl M J Kirkpatrick, Martina Kinzig, Ulrike Holzgrabe, George L Drusano, Ulrich Stephan, Fritz Sörgel.   

Abstract

Piperacillin in combination with tazobactam is one of the most commonly used intravenous antibiotics. There is evidence for a possible saturable elimination of piperacillin. Therefore, the saturable elimination and its impact on the choice of optimal dosage regimens were quantified. In a randomized crossover study, 10 healthy volunteers received 1,500 mg and 3,000 mg of piperacillin as 5-min intravenous infusion. Population pharmacokinetics based on plasma and urine data were determined utilizing NONMEM and S-ADAPT. Probabilities of target attainment (PTAs) were compared for different models and dosage regimens, based on the target time of the non-protein-bound concentration above the MIC of at least 50% of the dosing interval. Total clearance of piperacillin was 18% (geometric mean ratio, 90% confidence interval, 11 to 24%) lower (P < 0.01), and renal clearance was 24% (9 to 37%) lower (P = 0.02) at the high compared to the low dose. The final model included first-order nonrenal elimination and parallel first-order and mixed-order renal elimination. Nonrenal clearance was 5.44 liter/h (coefficient of variation, 18%), first-order renal clearance was 4.42 liter/h (47%), and the maximum elimination rate of mixed-order renal elimination was 219 mg/h (84%), with a Michaelis-Menten constant of 36.1 mg/liter (112%). Compared to models with saturable elimination, a linear model predicted up to 10% lower population PTAs for high-dose short-term infusions (6 g every 8 h) and up to 4% higher population PTAs for low-dose continuous infusions (6 g/day). While renal elimination of piperacillin was saturable at therapeutic concentrations, the extent of saturation of nonrenal clearance was small. The influence of saturable elimination on PTAs for clinically relevant dosage regimens was relatively small.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908169      PMCID: PMC3486597          DOI: 10.1128/AAC.00937-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  Animal model pharmacokinetics and pharmacodynamics: a critical review.

Authors:  D Andes; W A Craig
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

Review 2.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

3.  In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.

Authors:  Tanja Schülin
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

4.  Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  AAPS J       Date:  2011-03-04       Impact factor: 4.009

5.  Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Authors:  P G Ambrose; S M Bhavnani; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

Authors:  Joseph L Kuti; Charles H Nightingale; Richard Quintiliani; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2002-09       Impact factor: 2.803

7.  Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; M Kinzig; C B Landersdorfer; U Holzgrabe; U Stephan; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

8.  Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Authors:  Eric Viaene; Hugues Chanteux; Hélène Servais; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times.

Authors:  F B Spencker; L Staber; T Lietz; R Schille; A C Rodloff
Journal:  Clin Microbiol Infect       Date:  2003-05       Impact factor: 8.067

10.  Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

Authors:  Alexander A Vinks; Jan G Den Hollander; Shelley E Overbeek; Roger W Jelliffe; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more
  14 in total

Review 1.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

2.  Population pharmacokinetic analysis of piperacillin in burn patients.

Authors:  Sangil Jeon; Seunghoon Han; Jongtae Lee; Taegon Hong; Jeongki Paek; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.

Authors:  XiangQing Song; MingHui Long
Journal:  Int J Clin Pharm       Date:  2018-08-16

4.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

5.  Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Authors:  Maria Goul Andersen; Anders Thorsted; Merete Storgaard; Anders N Kristoffersson; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

7.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

8.  A mutation in the glycosyltransferase gene lafB causes daptomycin hypersusceptibility in Enterococcus faecium.

Authors:  Suelen S Mello; Daria Van Tyne; Francois Lebreton; Simone Q Silva; Mara C L Nogueira; Michael S Gilmore; Ilana L B C Camargo
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

Review 9.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

10.  Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design.

Authors:  Karin Kipper; Charlotte I S Barker; Joseph F Standing; Mike Sharland; Atholl Johnston
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.